Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997. It is grouped under the following drug class(es): Antineoplastic agents and Fertility agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Femara, Letrozol and letrozolum. Its PubChem CID is 3902.
Letrozole
| CAS No | 112809-51-5 |
|---|---|
| Molecular Formula | C17H11N5 |
| Molecular Weight | 285.30 g/mol |
| Synonyms | 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
The listed CAS number is 112809-51-5.
The listed molecular formula is C17H11N5.
The listed molecular weight is 285.30 g/mol.
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile.
The source lists Femara, Letrozol and letrozolum.